Zimmer will acquire all outstanding shares of Paragon stock for an upfront payment of $13 per share, corresponding to an equity value of approximately $1.1 billion and an enterprise value of approximately $1.2 billion, according to a Jan. 28 news release.
Paragon was founded in 2010 and offers surgical equipment and product systems spanning all major foot-and-ankle segments, including fracture and trauma, deformity correction and joint replacement.
The acquisition will expand Zimmer Biomet’s foot-and-ankle offerings and bolster its fracture and trauma, and joint-replacement portfolios.
Paragon estimated its net revenue for fiscal 2024 at about $255.9 million to $256.2 million, representing 18.2% to 18.4% reported growth over fiscal 2023, according to the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
